Company intelligence / Profile preview

Skin Analytics

Cambridge, England, United Kingdomskin-analytics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Skin Analytics’ DERM platform has been deployed at over two dozen NHS sites, triaging more than 150,000 patients and detecting over 14,000 cancers. Clinical studies show DERM can autonomously discharge up to 40% of urgent suspected cancer referrals with accuracy exceeding that of dermatologists (>99.8% vs. dermatologist’s ~98.9%), reducing unnecessary face-to-face appointments by up to 95%. NICE has conditionally recommended its use in the NHS while further evidence accumulates.

Therapeutic areas: OncologyDermatology
Modalities: Device (AI-powered medical device)Non-pharmacological therapy (AI-based diagnostic/triage tool)Software as a Medical Device (SaMD)
Industry: Digital Health Medical Devices

Partnerships

National Health Service/NHS Trusts across EnglandUniversity Hospital Birmingham

Beyond the preview

Go deeper on Skin Analytics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skin Analytics.

Explore the full profile